Eddie Hickman
Stock Analyst at Guggenheim
(3.33)
# 965
Out of 4,863 analysts
16
Total ratings
43.75%
Success rate
7.98%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eddie Hickman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $78 → $84 | $41.23 | +103.74% | 8 | May 2, 2025 | |
| PMN ProMIS Neurosciences | Reiterates: Buy | $6 | $0.51 | +1,069.59% | 2 | Apr 1, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $20 → $22 | $9.13 | +140.96% | 1 | Mar 13, 2025 | |
| GHRS GH Research | Initiates: Buy | $32 | $12.91 | +147.87% | 1 | Mar 13, 2025 | |
| CYBN Cybin | Initiates: Buy | $35 | $8.04 | +335.32% | 1 | Mar 13, 2025 | |
| OTLK Outlook Therapeutics | Reiterates: Buy | $12 | $1.77 | +577.97% | 3 | Jan 17, 2025 |
Tarsus Pharmaceuticals
May 2, 2025
Maintains: Buy
Price Target: $78 → $84
Current: $41.23
Upside: +103.74%
ProMIS Neurosciences
Apr 1, 2025
Reiterates: Buy
Price Target: $6
Current: $0.51
Upside: +1,069.59%
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $20 → $22
Current: $9.13
Upside: +140.96%
GH Research
Mar 13, 2025
Initiates: Buy
Price Target: $32
Current: $12.91
Upside: +147.87%
Cybin
Mar 13, 2025
Initiates: Buy
Price Target: $35
Current: $8.04
Upside: +335.32%
Outlook Therapeutics
Jan 17, 2025
Reiterates: Buy
Price Target: $12
Current: $1.77
Upside: +577.97%